Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2020-05-26 | 2020-04-07 |
| Drug Identification Number | 02224623 | 02224623 |
| Brand name | SOFRACORT | SOFRACORT |
| Common or Proper name | Sofracort | Sofracort |
| Company Name | CHEPLAPHARM ARZNEIMITTEL GMBH | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Ingredients | FRAMYCETIN SULFATE DEXAMETHASONE GRAMICIDIN | FRAMYCETIN SULFATE DEXAMETHASONE GRAMICIDIN |
| Strength(s) | 5MG 0.5MG 0.05MG | 5MG 0.5MG 0.05MG |
| Dosage form(s) | DROPS | DROPS |
| Route of administration | OPHTHALMIC OTIC OPHTHALMIC OTIC | OPHTHALMIC OTIC OPHTHALMIC OTIC |
| Packaging size | 8ml | 8ml |
| ATC code | S03CA | S03CA |
| ATC description | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2020-06-19 | 2020-05-01 |
| Actual start date | ||
| Estimated end date | 2020-08-15 | 2020-08-15 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Delay in production The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. | Delay in production The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. |
| Health Canada comments |